ArticleOncology letters2019
Effects of knockout of lincRNA-p21 on the proliferation, migration and invasion ability of HepG2 liver cancer cells.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Long noncoding RNAs (lncRNAs) in HIV-mediated carcinogenesis: Role in cell homeostasis, cell survival processes and drug resistance.Non-coding RNA research · 2022Review
- Cisatracurium inhibits the growth and induces apoptosis of ovarian cancer cells by promoting lincRNA-p21.Bioengineered · 2021Article
- Effects of mesenchymal stem cell-derived exosomes on oxidative stress responses in skin cells.Molecular biology reports · 2021Article
- Long Non-Coding RNA TRIM52-AS1 Promotes Growth and Metastasis via miR-218-5p/ROBO1 in Hepatocellular Carcinoma.Cancer management and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effects of long intergenic non-coding RNA (lincRNA)-p21 on the proliferation, migration and invasion ability of HepG2 liver cancer cells were assessed to explore the underlying mechanism. The lincRNA-p21 small interfering RNA (siRNA) lentivirus vector was constructed, transfected and screened to obtain a stable cell line, which constituted the experimental group. At the same time, the empty virus vector was transfected as the control group. The messenger RNA (mRNA) expression of lincRNA-p21 in cells was detected via reverse transcription-polymerase chain reaction (RT-PCR). The proliferation ability of cells was detected via Cell Counting kit-8 (CCK-8) assay. Transwell chamber experiment was used to observe cell migration and invasion ability. Compared with that in the control group, the mRNA expression level of lincRNA-p21 in cells in the experimental group was obviously decreased (p<0.05). Results of CCK-8 showed that the proliferation ability of liver cancer cells was remarkably higher than that in the control group after knockout of lincRNA-p21 (p<0.05). Results of the Transwell chamber experiment revealed that the invasion and migration ability of HepG2 cells in experimental group was markedly higher than that in control group (p<0.05). When lincRNA-p21 was inhibited, the proliferation, invasion and migration ability of HepG2 cells were significantly enhanced, and the apoptosis rate was significantly decreased. Thus, lincRNA-p21 on the surface may play an inhibitory role in the occurrence, development and metastasis of liver cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.